DeepMed Research

University of Pennsylvania

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1740-11-14

Employees: 5K

Market Cap: -

Website: http://www.upenn.edu

Clinical Trials

Liposomal Bupivacaine in Shoulder Arthroscopy

Phase 3

Withdrawn

Conditions: Rotator Cuff Tears

Interventions: Drug: Liposomal bupivacaine
Drug: Bupivacaine with Dexamethasone Solution

First Posted Date: 2020-07-08

Last Posted Date: 2024-03-12

Lead Sponsor: University of Pennsylvania

Registration Number: NCT04461028

Locations: 🇺🇸
Penn Presbyterian Medical Center, Philadelphia, Pennsylvania, United States

Terlipressin for HRS-AKI in Liver Transplant Candidates (INFUSE)

Phase 3

Completed

Conditions: Hepatorenal Syndrome

Interventions: Drug: Terlipressin

First Posted Date: 2020-07-07

Last Posted Date: 2024-10-09

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 50

Registration Number: NCT04460560

Locations: 🇺🇸
Baylor Scott and White All Saints Medical Center, Fort Worth, Texas, United States
🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
Piedmont Healthcare, Inc, Atlanta, Georgia, United States

and more 4 locations

Brain Mechanisms of Pharmacotherapy in Opioid Use Disorder

Phase 2

Not yet recruiting

Conditions: Opioid Dependence

Interventions: Drug: Vivitrol
Drug: Brixadi

First Posted Date: 2020-07-01

Last Posted Date: 2024-11-01

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 200

Registration Number: NCT04454411

TeamSTEPPS in School Mental Health

Not Applicable

Completed

Conditions: Multidisciplinary Communication
Interprofessional Relations
Child Behavior Problem

Interventions: Behavioral: TeamSTEPPS

First Posted Date: 2020-06-19

Last Posted Date: 2024-05-08

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 90

Registration Number: NCT04440228

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

BLOCKade of Calcium Channels and Beta Adrenergic Receptors for the Treatment of Hypertension in HFpEF

Phase 4

Completed

Conditions: Heart Failure with Preserved Ejection Fraction
Hypertension

Interventions: Drug: Metoprolol Succinate
Drug: Amlodipine Besylate

First Posted Date: 2020-06-17

Last Posted Date: 2025-01-09

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 50

Registration Number: NCT04434664

Locations: 🇺🇸
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Hyperfine Portable MRI in Hydrocephalus and Other Conditions Prompting Outpatient Brain Imaging

Not Applicable

Active, not recruiting

Conditions: Neurological Disorder
Hydrocephalus

Interventions: Device: Hyperfine MRI scan

First Posted Date: 2020-06-17

Last Posted Date: 2025-05-20

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 100

Registration Number: NCT04436068

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

Neuroendocrine and Adrenal Tumors

Withdrawn

Conditions: Neuroendocrine Tumors
Adrenal Tumor

Interventions: Other: No intervention

First Posted Date: 2020-06-16

Last Posted Date: 2025-02-10

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 999

Registration Number: NCT04432532

Incentives to Promote Sustained Linkage to HIV Care

Not Applicable

Completed

Conditions: Human Immunodeficiency Virus
HIV/AIDS

Interventions: Behavioral: Provision of HIV self-screen kit with incentives and linkage promotion

First Posted Date: 2020-06-16

Last Posted Date: 2022-07-20

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 99

Registration Number: NCT04431154

Locations: 🇿🇦
Ezintsha Clinical Research Center, Johannesburg, Gauteng, South Africa

Evaluating Cascade Communication Methods

Active, not recruiting

Conditions: BRCA2 Mutation
BRCA1 Mutation

First Posted Date: 2020-06-11

Last Posted Date: 2025-04-22

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 100

Registration Number: NCT04428736

Locations: 🇺🇸
Abramson Cancer Center, Philadelphia, Pennsylvania, United States

Retreatment With CTL019/CTL119

Phase 1

Not yet recruiting

Conditions: Lymphoma, B-Cell

Interventions: Drug: CD19 redirected autologous T cells (CTL019 or CTL119 cells)

First Posted Date: 2020-06-09

Last Posted Date: 2024-08-27

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 12

Registration Number: NCT04419909

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy